Clinical trials: Neuromuscular Disorder
Spasticity With Multiple Sclerosis
Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
This study will be conducted to evaluate the effect of multiple doses of nabiximols compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Lower Limb Muscle Tone-6 [LLMT-6]) in…
- Trial name
- RELEASE MSS5 (NCT04984278)
- Testing
- Nabiximols
- Where
- 30 sites in United States, Czechia and 3 more
- Volunteers
- 56 people
- Sponsor
- Jazz Pharmaceuticals
Dialysis
Effects of Exercise by Neuromuscular Stimulation in Dialysis Patients
The investigators propose a pilot feasibility study to determine if exercise delivered by passive electrical muscle stimulation (EMS) in patients with end stage renal disease (ESRD) on hemodialysis improves physical fitness and…
- Trial name
- NCT03517553
- Testing
- EMS users in ESRD
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Iowa
Fibromyalgia, Myofascial Pain Syndromes
A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
The use of low-dose CBP dosed nightly at bedtime for FM was supported by the results of Tonix' TNX-CY-F202 Phase 2b study (also referred to as the BESTFIT Study).
- Conditions
- Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Musculoskeletal Diseases
- Trial name
- AFFIRM (NCT02436096)
- Testing
- TNX-102 SL Tablet, 2.8mg
- Where
- 35 sites in United States
- Volunteers
- 519 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Muscle Weakness
Functional Change With MMS
Evaluate the safety and efficacy of magnetic muscle stimulation (MMS) of abdominal muscle.
- Trial name
- FMS (NCT04506502)
- Testing
- The ZELTIQ System
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Zeltiq Aesthetics
Drug Effect, Rib Fractures
Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures
Rib fractures represent a common injury pattern this is highly associated with patient morbidity and mortality, as pain control remains a challenge.
- Conditions
- Drug Effect, Rib Fractures, Rib Trauma, Surgical Procedure, Unspecified
- Trial name
- NCT03305666
- Testing
- Liposomal bupivacaine injection, Bupivacaine indwelling catheter
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Denver Health and Hospital Authority
Amyotrophic Lateral Sclerosis (ALS)
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
This is a multi-center, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of autologous (self) transplantation of Neurotrophic factors-secreting Mesenchymal Stromal Cells (MSC-NTF, NurOwn™) in…
- Trial name
- NurOwn (NCT02017912)
- Testing
- Nurown MSC-NTF cells
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Brainstorm-Cell Therapeutics
Muscle Spasticity
Retrospective Study of Patients With Spasticity in the Spanish Population
This is a retrospective study of patients with spasticity in the Spanish population.
- Trial name
- NCT01383681
- Testing
- No treatment
- Where
- Spain
- Volunteers
- 235 people
- Sponsor
- Allergan
Tetanus, Hepatitis B
Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants
This study will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083 vaccine co-administered with Prevenar 13® at 2, 4 and 12 months of age and with Rotarix™ at 2 and 4 months of age.
- Conditions
- Tetanus, Hepatitis B, Haemophilus Influenzae Type b, Poliomyelitis
- Trial name
- NCT01090453
- Testing
- GSK2202083A vaccine, Prevenar 13®, Infanrix hexa™
- Where
- 34 sites in Canada, France and 1 more
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Amyotrophic Lateral Sclerosis
Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)
This is an open label study with 30-day run in phase to establish baseline parameters, 90-day treatment phase, and a 90-day withdrawal phase to determine long-term effects, duration of treatment response, and potential effects of…
- Trial name
- EPI-589 (NCT02460679)
- Testing
- EPI-589
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- PTC Therapeutics
Duchenne Muscular Dystrophy
Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy
This is a Phase 2/3, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension period to evaluate the safety and efficacy of WVE-210201 (suvodirsen) in ambulatory male pediatric patients with…
- Trial name
- DYSTANCE 51 (NCT03907072)
- Testing
- WVE-210201 (suvodirsen)
- Where
- 22 sites in United States, Belgium and 6 more
- Volunteers
- 6 people
- Sponsor
- Wave Life Sciences USA, Inc.
Small Fiber Neuropathy
A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy of VX-150 for the treatment of pain caused by small fiber neuropathy.
- Trial name
- NCT03304522
- Testing
- VX-150
- Where
- 34 sites in United States, Germany and 2 more
- Volunteers
- 89 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Primary Fibromyalgia
Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia
The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacokinetics of milnacipran in pediatric patients aged 13 to 17 years with primary fibromyalgia.
- Trial name
- MyFi (NCT01328002)
- Testing
- Milnacipran
- Where
- 47 sites in United States
- Volunteers
- 116 people
- Sponsor
- Forest Laboratories
Neurofibromatosis Type 1, Plexiform Neurofibromas
Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain
Background: People with neurofibromatosis type I (NF1) and plexiform neurofibroma (PN) tumors often have chronic pain that his hard to control.
- Trial name
- NCT02471339
- Testing
- Acceptance and Commitment Therapy (ACT)
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Becker Muscular Dystrophy
(-)- Epicatechin Becker Muscular Dystrophy
This is a 48-week open-label extension of our initial proof-of-concept study (UCD0113) in patients with Becker muscular dystrophy who participated in the earlier trial.
- Trial name
- NCT03236662
- Testing
- (-)-Epicatechin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Craig McDonald, MD
Multiple Sclerosis, Spasticity
A Study of the Long-term Safety of Sativex Use
Subjects who had previously received GW-1000-02 in a GW study who opted to continue using it in the long-term were monitored for ongoing tolerability and evidence of clinical benefit.
- Conditions
- Multiple Sclerosis, Spasticity, Pain
- Trial name
- NCT01606137
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 507 people
- Sponsor
- Jazz Pharmaceuticals
Fibromyalgia
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In Patients With Fibromyalgia
This study will assess the safety and efficacy of the long-term use of pregabalin at doses up to 450 mg/day in patients with fibromyalgia who have completed 16 weeks of dosing in Study A0081208 (NCT00830167).
- Trial name
- NCT00830128
- Testing
- pregabalin (Lyrica)
- Where
- 19 sites in Japan
- Volunteers
- 106 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Fibromyalgia
Testing Mestinon and Exercise in Fibromyalgia
The purpose of this trial was to test the combined and independent effects of 6 months of exercise and Mestinon in people with fibromyalgia.
- Trial name
- NCT00535587
- Testing
- Exercise, pyridostigmine, Placibo
- Where
- United States
- Volunteers
- 178 people
- Sponsor
- Oregon Health and Science University
Multiple Sclerosis, Spasticity, Muscle
A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS
Spasticity is a common complication in MS and occurs in up to 84% of patients. The main sign of spasticity is resistance to passive limb movement characterized by increased resistance to stretching, clonus, and exaggerated deep…
- Trial name
- OS440-3005 (NCT03319732)
- Testing
- Arbaclofen
- Where
- United States
- Volunteers
- 323 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Sarcopenia
A Study of Muscle Strength Maintenance in Older Adults
This research study is being done to see whether losartan can prevent the decrease in strength associated with aging. Muscle loss is associated with aging and has multiple symptoms such as weakness, slowness, and fatigue…
- Trial name
- NCT01989793
- Testing
- Losartan
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Muscle Atrophy, Muscle Weakness
Neuromodulation for Prevention of Intensive Care Unit Acquired Weakness and Post Intensive Care Syndrome
Post-intensive care syndrome (PICS) encompasses persistent physical, cognitive, and psychiatric symptoms following ICU discharge, commonly triggered by serious conditions such as respiratory failure, sepsis, and mechanical…
- Conditions
- Muscle Atrophy, Muscle Weakness, Blood Flow
- Trial name
- NCT06238609
- Testing
- Intervention Group, Control Group
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Bijan Najafi, PhD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.